169 related articles for article (PubMed ID: 22949056)
21. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA mutation status in Japanese lung cancer patients.
Kawano O; Sasaki H; Endo K; Suzuki E; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Nov; 54(2):209-15. PubMed ID: 16930767
[TBL] [Abstract][Full Text] [Related]
23. Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors.
Alì G; Boldrini L; Capodanno A; Pelliccioni S; Servadio A; Crisman G; Picchi A; Davini F; Mussi A; Fontanini G
Exp Ther Med; 2011 Sep; 2(5):787-792. PubMed ID: 22977576
[TBL] [Abstract][Full Text] [Related]
24. Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA.
Shalmon B; Drendel M; Wolf M; Hirshberg A; Cohen Y
Int J Oral Maxillofac Surg; 2016 Jun; 45(6):721-5. PubMed ID: 26811072
[TBL] [Abstract][Full Text] [Related]
25. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Wu G; Mambo E; Guo Z; Hu S; Huang X; Gollin SM; Trink B; Ladenson PW; Sidransky D; Xing M
J Clin Endocrinol Metab; 2005 Aug; 90(8):4688-93. PubMed ID: 15928251
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
27. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
28. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
[TBL] [Abstract][Full Text] [Related]
29. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
30. PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
Deb S; Do H; Byrne D; Jene N; ; Dobrovic A; Fox SB
Breast Cancer Res; 2013; 15(4):R69. PubMed ID: 23971979
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
32. Expression of the E-cadherin-catenin complex in lung neuroendocrine tumours.
Clavel CE; Nollet F; Berx G; Tejpar S; Nawrocki-Raby B; Kaplan HH; van Roy FM; Birembaut PL
J Pathol; 2001 May; 194(1):20-6. PubMed ID: 11329137
[TBL] [Abstract][Full Text] [Related]
33. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
[TBL] [Abstract][Full Text] [Related]
34. TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location.
Du EZ; Goldstraw P; Zacharias J; Tiffet O; Craig PJ; Nicholson AG; Weidner N; Yi ES
Hum Pathol; 2004 Jul; 35(7):825-31. PubMed ID: 15257545
[TBL] [Abstract][Full Text] [Related]
35. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
36. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
37. The PIK3CA gene is mutated with high frequency in human breast cancers.
Bachman KE; Argani P; Samuels Y; Silliman N; Ptak J; Szabo S; Konishi H; Karakas B; Blair BG; Lin C; Peters BA; Velculescu VE; Park BH
Cancer Biol Ther; 2004 Aug; 3(8):772-5. PubMed ID: 15254419
[TBL] [Abstract][Full Text] [Related]
38. Mutations of PIK3CA are rare in cutaneous melanoma.
Omholt K; Kröckel D; Ringborg U; Hansson J
Melanoma Res; 2006 Apr; 16(2):197-200. PubMed ID: 16567976
[TBL] [Abstract][Full Text] [Related]
39. PIK3CA mutations and copy number gains in human lung cancers.
Yamamoto H; Shigematsu H; Nomura M; Lockwood WW; Sato M; Okumura N; Soh J; Suzuki M; Wistuba II; Fong KM; Lee H; Toyooka S; Date H; Lam WL; Minna JD; Gazdar AF
Cancer Res; 2008 Sep; 68(17):6913-21. PubMed ID: 18757405
[TBL] [Abstract][Full Text] [Related]
40. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]